Vyome (HIND) investor relations material

Executive summary

• Completed a reverse merger with Reshape Lifesciences in August 2025, resulting in a Nasdaq listing and a new focus on immuno-inflammatory and rare disease therapeutics.

• Lead program VT-1953 is advancing toward pivotal FDA discussions in 2026; other pipeline assets include VT-1908 and VB-1953, with the latter Phase 3-ready.

• Commercialized antifungal products in India through Sun Pharma; legacy licensing agreements continue to generate minor royalties.

• Entered an exclusive global license for preclinical JAK inhibitor assets from Impetis Biosciences in May 2026, with only a 1.5% royalty on future net sales.

Financial highlights

• Revenue for Q1 2026 was $31,591, down from $198,581 in Q1 2025, reflecting the wind-down of legacy Sun Pharma agreements.

• Net loss increased to $985,521 in Q1 2026 from $293,974 in Q1 2025, driven by higher R&D and G&A expenses.

• Cash and cash equivalents rose to $8.8 million at March 31, 2026, up from $5.0 million at year-end 2025, due to ATM equity sales.

• Research and development expenses surged to $666,405 in Q1 2026 from $90,268 in Q1 2025, reflecting increased activity in lead programs.

• General and administrative expenses rose to $477,575 in Q1 2026 from $259,626 in Q1 2025, mainly due to merger-related costs and stock-based compensation.

Outlook and guidance

• Management expects continued operating losses and increased R&D spending as clinical programs advance.

• Current cash is expected to fund operations for at least 15 months, including the initiation of a pivotal trial for VT-1953, but not through completion.

• Additional capital will be required to complete clinical trials and support broader pipeline development.